Bristol Myers Squibb - News
WEBSep 9, 2024 — Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBSep 9, 2022 — Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb…
WEBJun 24, 2022 — Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Pharmaceutical press releases & news - Bristol Myers Squibb
WEBExplore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines, research innovation and other news as we work to support patients fighting serious disease.
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy ...
WEBOct 24, 2023 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
WEBOct 8, 2023 — Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset...
Global Biopharmaceutical Company - Bristol Myers Squibb
WEBBristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
US FDA approves expanded use of Bristol Myers' cancer cell …
WEBMay 15, 2024 — The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called...
Bristol Myers Squibb sues Biden administration over Medicare …
WEBJun 16, 2023 — Bristol Myers Squibb on Friday sued the Biden administration over Medicare ’s new powers to slash drug prices, the third such lawsuit to be filed against the program in a matter of days. The ...
Bristol Myers Squibb Announces 10-Year Strategy to Reach More …
WEBPRINCETON, N.J., May 22, 2024 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, …
Skip to content